List of Excipients in Branded Drug ANCOBON

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Bausch Health US LLC	ANCOBON	flucytosine	0187-3554	D&C YELLOW NO. 10
Bausch Health US LLC	ANCOBON	flucytosine	0187-3554	FD&C BLUE NO. 1
Bausch Health US LLC	ANCOBON	flucytosine	0187-3554	FD&C YELLOW NO. 6
Bausch Health US LLC	ANCOBON	flucytosine	0187-3554	GELATIN
Bausch Health US LLC	ANCOBON	flucytosine	0187-3554	LACTOSE

ANCOBON Excipient Strategy and Commercial Opportunities for Flucytosine

Last updated: August 1, 2026

ANCOBON is the former U.S. brand for flucytosine, an oral antifungal used primarily with amphotericin B for cryptococcal meningitis and selected Candida infections. Its commercial value is driven less by broad market volume than by clinical necessity, limited substitutes, therapeutic-drug-monitoring requirements, and recurring shortages. The strongest excipient opportunities are not basic capsule reformulations. They are pediatric liquid products, ready-to-use hospital formulations, stability improvements, taste masking, and dosage forms that reduce compounding and administration risk.

What is ANCOBON and how is flucytosine used?

ANCOBON contains flucytosine, also known as 5-fluorocytosine or 5-FC. It is a fluorinated pyrimidine antifungal that enters fungal cells and is converted into active metabolites that inhibit DNA and RNA synthesis.

Attribute	ANCOBON / flucytosine
Active ingredient	Flucytosine
Drug class	Antifungal antimetabolite
Primary uses	Cryptococcal meningitis; serious Candida infections
Common regimen	Usually combined with amphotericin B
U.S. dosage form	Immediate-release capsules
Strengths historically marketed	250 mg and 500 mg
Administration	Oral
Key pharmacokinetic issue	Predominantly renal elimination
Key safety risks	Bone-marrow suppression, hepatotoxicity, gastrointestinal toxicity
Monitoring	Renal function, blood counts, liver function, and plasma concentrations where appropriate
Regulatory status	FDA-approved product historically marketed as ANCOBON; current U.S. availability is primarily associated with generic flucytosine products

The drug has high oral bioavailability, generally reported at approximately 80% to 90%, which reduces the need for a complex delivery system. Its main formulation challenges are practical: capsule swallowing, dose flexibility, palatability, renal-dose adjustment, and reliable supply.

What excipients are used in ANCOBON capsules?

ANCOBON capsules use a conventional immediate-release solid oral formulation. Public labeling identifies inactive ingredients associated with the capsule fill and shell, including conventional diluents, lubricants, glidants, surfactants, and gelatin-based capsule materials. Exact inactive-ingredient descriptions can vary by product presentation and label revision, so commercial development should rely on the current FDA-approved product labeling and supplier certificates rather than historical brand records alone.[1]

Typical excipient functions include:

Excipient function	Commercial purpose in flucytosine capsules
Diluent or filler	Provides capsule-fill mass and dose uniformity
Binder	Supports granule or powder cohesion
Glidant	Improves powder flow during encapsulation
Lubricant	Reduces sticking and manufacturing friction
Surfactant	Supports wetting and dissolution
Capsule shell	Provides oral presentation and product protection
Opacifier or colorant	Supports identification, appearance, and light protection

The conventional capsule approach is technically low risk. Flucytosine is highly water soluble, and the product does not require a lipid system, enteric coating, modified release, or complex bioavailability enhancement. A new capsule would therefore need to create value through manufacturing reliability, excipient compatibility, patient usability, or regulatory differentiation.

What excipient strategy is appropriate for a flucytosine generic?

A practical excipient strategy should begin with a Q1/Q2-equivalent immediate-release capsule, followed by targeted differentiation only where it solves a documented clinical or supply problem.

1. Use a conservative capsule formulation for the base product

The lowest-risk formulation would use widely accepted oral excipients with established regulatory precedents:

• Microcrystalline cellulose or an alternative direct-compression diluent
• Colloidal silicon dioxide for flow
• Magnesium stearate or another compatible lubricant
• A low-level wetting agent where dissolution testing supports its use
• Gelatin or a suitable vegetarian capsule shell
• Titanium dioxide or permitted colorants for identification

The formulation should avoid unnecessary excipient novelty. Flucytosine has a narrow therapeutic margin in patients with renal impairment, so the pivotal development objective is dose accuracy and predictable dissolution, not enhanced exposure.

2. Control excipient-related variability

Flucytosine is usually dosed several times daily and may be used in critically ill patients. Manufacturing controls should address:

• Content uniformity at both 250 mg and 500 mg strengths
• Powder segregation during encapsulation
• Capsule-fill weight variation
• Dissolution across physiologic pH conditions
• Moisture uptake
• Long-term chemical stability
• Impurity formation
• Compatibility with capsule-shell materials
• Stability under hospital storage and transport conditions

A direct-compression or dry-granulation process could reduce dependence on water and shorten manufacturing time. The commercial benefit would be strongest if it improves supply reliability or permits production by a contract manufacturer with limited wet-processing capacity.

3. Consider a non-gelatin capsule shell

A vegetarian capsule could support hospital formularies, religious or dietary requirements, and international procurement. Hydroxypropyl methylcellulose shells may also offer a cleaner positioning for some buyers. The value is limited, however, unless the shell provides measurable stability, supply, or procurement advantages.

A shell change would require comparative dissolution, moisture-permeation, stability, and bioequivalence work. It would not ordinarily create meaningful patent protection by itself unless combined with a defined composition and performance limitation.

What formulation opportunities exist beyond ANCOBON capsules?

The largest opportunities are formulations that address administration barriers rather than pharmacology.

Is there an opportunity for a flucytosine oral suspension?

Yes. A stable oral suspension is the clearest formulation opportunity.

Flucytosine is frequently used in patients who may have difficulty swallowing capsules, including critically ill adults, patients with neurologic disease, and pediatric patients. Hospitals may rely on extemporaneous compounding when commercial liquid products are unavailable. A sponsor could develop:

• A ready-to-use suspension
• A powder for reconstitution
• A concentrated suspension for pharmacy dilution
• Unit-dose oral syringes
• A preservative-free formulation for short-term hospital use

The formulation would need to address:

• High aqueous solubility and the resulting need for dose control
• Sedimentation and redispersibility
• Taste masking
• Chemical stability after reconstitution
• Microbial control
• Syringe compatibility
• Compatibility with enteral feeding tubes
• Accurate delivery across renal-adjusted doses

A liquid product could support pediatric dosing and more precise renal adjustment. It could also reduce capsule manipulation in hospitals. The principal patent opportunity would involve a defined excipient system, pH range, preservative or preservative-free approach, container-closure system, and stability profile.

Can taste masking create a defensible product?

Potentially, but the claim scope must be carefully designed. Taste masking could use:

• Ion-exchange resins
• Polymer coatings
• Lipid or wax matrices
• Cyclodextrin complexes
• Sweetener and flavor systems
• Microencapsulation
• Multiparticulate granules

A taste-masked formulation would be commercially relevant for pediatric use, but excessive coating could delay dissolution or reduce bioavailability. The preferred design would maintain immediate release while reducing bitterness during oral administration.

A patent could target the combination of flucytosine particles with a defined coating polymer, particle-size distribution, coating weight gain, dissolution profile, and sensory threshold. A broad claim to “flucytosine with a taste-masking agent” would face substantial prior-art risk.

Are modified-release flucytosine products commercially attractive?

Usually not. The established therapeutic use involves frequent dosing and combination therapy. Modified release could reduce administration frequency, but it would introduce formulation complexity without solving the primary market constraints of supply, monitoring, and renal toxicity.

A sustained-release product would also require proof that exposure remains therapeutically effective and does not increase toxicity in patients with impaired renal clearance. The development cost and regulatory burden would likely exceed the addressable market unless a sponsor has a strong hospital or global-health procurement strategy.

Could injectable flucytosine create a new market?

An injectable product could address patients unable to absorb oral medication, but it would compete with the established role of amphotericin B in severe disease. Development would involve substantial sterile manufacturing, compatibility, stability, and clinical bridging work. The opportunity is technically possible but less attractive than an oral liquid or hospital-ready oral presentation.

What patents protect ANCOBON and flucytosine formulations?

The original composition-of-matter protection for flucytosine is long expired. ANCOBON is an old small-molecule product, and the commercial formulation does not appear to be protected by a current foundational patent estate comparable to that of a recently approved branded drug.

The relevant intellectual-property landscape is likely to consist of:

1. Historical compound patents that have expired.
2. Historical product or process patents with expired terms.
3. Generic formulation patents, if any, directed to specific excipient combinations.
4. Manufacturing-process patents.
5. Packaging, stability, or liquid-formulation patents for newly developed products.
6. Regulatory exclusivity, if granted for a new formulation or pediatric indication.

A new sponsor should not assume that a new excipient combination produces meaningful exclusivity. Patent strength would depend on whether the formulation delivers a measurable technical result, such as:

• Extended room-temperature stability
• Improved redispersibility
• Reduced degradation
• Improved taste scores
• Improved enteral-tube delivery
• Reduced capsule-fill variability
• Preservative-free multidose stability
• Improved moisture protection
• Reduced administration errors

What patent claims could protect a new flucytosine product?

Potential claim categories include:

Claim type	Potential subject matter	Relative strength
Composition	Flucytosine plus defined excipient concentrations	Moderate if technically narrow
Suspension	Particle size, pH, viscosity, sedimentation, and stability limits	Moderate to strong if data-supported
Taste masking	Coated particles or multiparticulates with defined dissolution	Moderate
Manufacturing process	Dry granulation, coating, blending, or encapsulation parameters	Moderate
Container-closure	Packaging that controls moisture or supports stability	Usually narrow
Method of use	Pediatric dosing, renal-adjusted administration, or administration through a feeding tube	Variable
Combination therapy	Flucytosine with amphotericin B under a defined regimen	Often vulnerable to prior art
Device	Unit-dose syringe, adapter, or administration system	Moderate if integrated with formulation

For U.S. commercialization, the sponsor should separate patent value from regulatory value. A narrow formulation patent may protect a differentiated product but may not prevent a competitor from marketing a conventional capsule.

When does ANCOBON lose exclusivity, and what is the FDA status?

The original ANCOBON exclusivity period has expired. Flucytosine is an established active ingredient, and generic versions can be approved through the abbreviated new drug application pathway when they meet FDA requirements for pharmaceutical equivalence and bioequivalence.

The relevant FDA issues are:

• Whether the reference-listed drug is currently marketed
• Whether the proposed product can use a standard ANDA pathway
• Whether the dosage form and strength are eligible for an ANDA
• Whether a liquid or other new dosage form requires a separate 505(b)(2) application
• Whether an approved product has an active patent listed in the Orange Book
• Whether any pediatric exclusivity or other statutory exclusivity applies

A new oral suspension may not fit cleanly within a conventional ANDA if there is no suitable reference product in the same dosage form. That could make a 505(b)(2) pathway more relevant, particularly if the sponsor relies on published flucytosine safety and efficacy information while conducting bridging studies for the new formulation.[2]

What is the Orange Book status of ANCOBON?

The Orange Book analysis should focus on the current reference-listed drug and active listings, not only the historical brand name. ANCOBON’s original product protections are not the principal barrier to entry. The practical barriers are more likely to be:

• Limited commercial demand
• Product discontinuation or availability changes
• Bioequivalence testing
• API sourcing
• Manufacturing economics
• Hospital purchasing requirements
• Supply continuity
• Regulatory documentation for a scarce product

If an active patent is listed against a current flucytosine product, an ANDA applicant could face a Paragraph IV certification. For an old immediate-release capsule, the probability of a durable, broad patent barrier is low. A newly developed liquid or taste-masked product could create its own patent estate, but that estate would protect only the claimed formulation and related uses.

What Paragraph IV challenges and litigation affect flucytosine?

Flucytosine does not have the high-volume Paragraph IV litigation profile associated with major branded medicines. The historical age of the active ingredient and the conventional capsule formulation reduce the likelihood of commercially significant patent litigation.

The more relevant legal risks for a new entrant are:

• Patent disputes over a newly developed liquid formulation
• Hatch-Waxman litigation involving formulation or method-of-use patents
• Trade-secret disputes involving manufacturing processes
• Supplier exclusivity or API-quality disputes
• Regulatory disputes concerning reference-product availability
• Antitrust or supply-contract issues if a small number of manufacturers control procurement channels

No material settlement framework should be assumed for the historical ANCOBON capsule absent a specific, active patent dispute. A new entrant would have greater litigation exposure if it launches a differentiated formulation that overlaps with a recent 505(b)(2) product.

Which companies are challenging ANCOBON, and how competitive is the market?

Competition is primarily from generic flucytosine manufacturers and distributors rather than from branded antifungal companies. The market has limited demand because flucytosine is used mainly in specialized infectious-disease settings. That same low volume can discourage manufacturers and create supply fragility.

The competitive landscape includes:

• Generic capsule manufacturers
• Hospital and specialty-pharmacy distributors
• Compounding pharmacies
• International suppliers
• Amphotericin B manufacturers offering the complementary component of combination therapy
• Potential sponsors of pediatric or liquid formulations

The strongest competitive advantage would not be a small reduction in capsule price. It would be dependable supply, validated hospital handling, pediatric usability, and reliable availability during infectious-disease outbreaks or regional shortages.

What commercial opportunities exist for ANCOBON excipient innovation?

Pediatric and neonatal use

A palatable liquid could expand access in pediatric patients and support weight-based dosing. A 100 mg/mL or other clinically practical concentration could reduce administration volume, but concentration selection would need to balance dose accuracy, solubility, taste, and stability.

Hospital-ready packaging

Unit-dose oral syringes, blister packs, and enteral-tube-compatible presentations could reduce pharmacy labor. A powder-for-reconstitution product could lower shipping weight and improve stability, but it would create preparation requirements.

Global-health procurement

Cryptococcal meningitis remains a major treatment concern in people with advanced HIV infection. The World Health Organization has identified flucytosine as an important component of antifungal treatment strategies, particularly in combination regimens for cryptococcal disease.[3] Commercial opportunities may therefore exist through:

• Tender supply
• Fixed-dose or co-packaged antifungal regimens
• Stable products for low-resource settings
• Heat- and humidity-resistant packaging
• Smaller pack sizes
• Public-sector procurement agreements

Supply-chain resilience

A manufacturer that secures qualified API suppliers, dual-source excipients, and redundant encapsulation capacity may gain share without owning a strong formulation patent. For an old anti-infective, supply continuity can be a more valuable commercial differentiator than minor formulation changes.

Combination packaging

A co-pack containing flucytosine and amphotericin B could simplify treatment initiation. A fixed-dose combination would be more difficult because the products have different dosage forms, dosing schedules, and stability requirements. Co-packaging is more realistic than a single dosage form.

How strong is the patent estate for a new flucytosine formulation?

A conventional capsule patent estate would be weak because of the long history of flucytosine use and extensive prior art. A technically differentiated oral liquid could produce a stronger but still narrow estate.

Opportunity	Patent potential	Regulatory complexity	Commercial attractiveness
Conventional 250 mg/500 mg capsule	Low	Low to moderate	Moderate if supply is reliable
Vegetarian capsule	Low to moderate	Moderate	Limited
Taste-masked pediatric capsule	Moderate	Moderate	Moderate to high
Ready-to-use oral suspension	Moderate to strong	Moderate to high	High
Powder for reconstitution	Moderate	Moderate to high	Moderate
Enteral-tube formulation	Moderate	Moderate	High in hospitals
Modified-release capsule	Moderate	High	Low to moderate
Injectable formulation	Potentially strong	High	Uncertain
Co-pack with amphotericin B	Moderate commercial protection	Moderate	Moderate

What generic launch scenarios exist for flucytosine?

Scenario 1: Conventional generic capsule launch

This is the fastest regulatory route but offers limited differentiation. Success depends on API cost, manufacturing scale, wholesaler access, and contract supply.

Scenario 2: Premium hospital formulation

A sponsor launches a liquid, tube-compatible, or unit-dose product. The product may support higher pricing because it reduces compounding and administration burden. Patent protection is possible if the formulation has defined technical performance.

Scenario 3: Shortage-driven entry

A manufacturer enters after supply disruption or product discontinuation. The commercial opportunity is real but volatile. FDA shortage information, wholesaler inventories, and hospital purchasing data become critical launch indicators.[4]

Scenario 4: Global-health supply model

A supplier targets public-sector tenders and international HIV and cryptococcal-disease programs. Margin may be lower, but volume and procurement visibility can improve.

Key Takeaways

• ANCOBON is the historical brand for flucytosine, an old oral antifungal with expired foundational exclusivity.
• The conventional capsule formulation has low patent defensibility and limited differentiation.
• A stable, palatable oral suspension is the strongest excipient-led commercial opportunity.
• Pediatric dosing, enteral-tube administration, renal-dose flexibility, and hospital-ready packaging are the most credible product advantages.
• A new formulation patent should claim defined excipient systems and measurable performance, not generic excipient combinations.
• The main market risks are small volume, API availability, low manufacturer participation, and irregular hospital demand.
• The main commercial advantage is supply reliability combined with a formulation that reduces pharmacy compounding and administration problems.
• Any new liquid or specialty formulation may require a 505(b)(2) strategy rather than a conventional ANDA, depending on the available reference product.
• Flucytosine’s global-health role creates procurement opportunities, particularly for cryptococcal meningitis treatment programs.

FAQs

Is flucytosine still commercially available in the United States?

Generic flucytosine products are the relevant U.S. supply source. Availability can vary by manufacturer, distributor, and shortage conditions.

What is the best excipient for masking flucytosine’s taste?

No single excipient is universally optimal. Polymer-coated particles, ion-exchange resins, and flavor-sweetener systems are the leading development approaches, subject to dissolution and stability results.

Can a pharmacy compound flucytosine liquid from capsules?

Extemporaneous compounding may be used when a commercial liquid is unavailable, but stability, concentration, microbial control, and dose uniformity must be validated for the specific preparation.

Does flucytosine require a biologic or biosimilar strategy?

No. Flucytosine is a small-molecule drug. Biosimilar pathways do not apply; generic ANDA or, for certain new formulations, 505(b)(2) pathways are more relevant.

Would a flucytosine-amphotericin combination product be patentable?

A combination product could be patentable if it includes a novel formulation, packaging system, dosing schedule, or stability solution. A basic claim covering the known clinical combination would face substantial prior-art risk.

References

1. U.S. Food and Drug Administration. (n.d.). ANCOBON (flucytosine) capsule prescribing information. DailyMed and FDA labeling records.

2. U.S. Food and Drug Administration. (2023). Approved drug products with therapeutic equivalence evaluations (Orange Book). https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files

3. World Health Organization. (2022). WHO guidelines for diagnosing, preventing and managing cryptococcal disease among adults, adolescents and children living with HIV. World Health Organization.

4. U.S. Food and Drug Administration. (n.d.). Drug shortages. https://www.accessdata.fda.gov/scripts/drugshortages/